Drug intelligence / Profile preview

fluticasone

Development stage
Approved
Lead developer
GSK
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Inhalation, Intranasal, Topical
01

Overview

Fluticasone is a synthetic glucocorticoid corticosteroid available as two main esters—fluticasone propionate and fluticasone furoate. It is used in various formulations (inhalers, nasal sprays, topical creams) for the treatment of asthma, chronic obstructive pulmonary disease (COPD), allergic and non-allergic rhinitis, and corticosteroid-responsive dermatoses[4][5][7][8]. The drug acts primarily by binding to glucocorticoid receptors to produce potent anti-inflammatory effects. This action leads to the downregulation of multiple inflammatory mediators such as histamine, cytokines, leukotrienes, chemokines, prostaglandins, and tryptase[6]. Fluticasone interrupts both early- and late-phase allergic responses by controlling gene expression related to inflammation[6]. It was first approved in 1990 (propionate) and 2007 (furoate)[7].

Brand names
FlonaseFlonase Allergy Relief
Other names
fluticasone propionatefluticasone furoate
02

Targets

MR (Mineralocorticoid receptor)GR (Glucocorticoid receptor)PLA2G4A (Cytosolic phospholipase A2 alpha)PR (Progesterone receptor)

Beyond the preview

Go deeper on fluticasone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluticasone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call